Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors

Official title

A Dose Finding Study of MiniBeam RadioTherapy for Skin and Superficial Soft Tissue Tumors (MBRT1)

Overview

This clinical trial tests the safety and best dose of minibeam radiation therapy (MBRT) with a tungsten slit collimator for treating patients with skin or soft tissue tumors that have come back after a period of improvement (recurrent) or that spread from where they first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Tungsten is an extremely dense metal and is commonly used for blocking x-rays for minimum radiation exposure. A tungsten slit collimator is a device that separates an initially wide beam of x-rays into several very narrow individual beams of radiation. As radiation passes through the collimator, the radiation hits regions of solid tungsten and is blocked. In the open slit regions, radiation passes through to the intended target/tumor area defined by the physician. The tungsten slit collimator then selectively blocks portions of the radiation to create an alternating pattern of higher "peak" and lower "valley" radiation dose regions. These narrow beams of radiation are referred to as "minibeams" and the general approach referred to as MBRT.

Detailed description

PRIMARY OBJECTIVE:

I. To determine the maximum tolerated dose (MTD) of MBRT and describe the adverse events of treatment.

SECONDARY OBJECTIVE:

I. To assess the ability to maintain a distinct differential between peak and valley doses using film dosimetry.

EXPLORATORY OBJECTIVES:

I. To estimate the rate of freedom from local progression at 6 and 12 months after the start of MBRT.

II. To evaluate pre-treatment and post-treatment differential abundance of peripheral blood immune cell populations and their activation markers.

III. Explore germline and somatic mutations in homologous recombination (HR) genes and their association with freedom from local progression.

IV. Quantify the immune phenotypes and cell signaling in the tumor microenvironment pre-MBRT and post-MBRT using bulk ribonucleic acid (RNA)-sequencing (seq) data.

OUTLINE:

Patients undergo MBRT with a tungsten slit collimator over 2-3 fractions on study. Patients also undergo standard of care CT simulation on study and undergo collection of blood samples and punch or core biopsy throughout the study.

After completion of study treatment, patients are followed up at weeks 2, 4, and 12, and months 6, 9, and 12.

Interventions

• Procedure Biopsy Procedure
  Undergo biopsy
• Procedure Biospecimen Collection
  Undergo collection of blood samples
• Procedure Computed Tomography
  Undergo CT
• Other Medical Device Usage and Evaluation
  Undergo MBRT with tungsten slit collimator
• Radiation Minibeam Radiation Therapy
  Undergo MBRT with tungsten slit collimator

Primary outcome measures

• Maximum tolerated dose [Time frame: Up to 28 days]
• Incidence of adverse events [Time frame: Up to 12 months]

Secondary outcome measures (2)

• Ability to maintain a distinct differential between peak and valley doses using film dosimetry [Time frame: Up to 12 months]
• Incidence of adverse events [Time frame: At months 6, 9, and 12]

Eligibility criteria

Inclusion criteria

• Age ≥ 18 years
• Histologically confirmed malignancy
• Primary, recurrent, or metastatic skin or superficial soft tissue tumor amenable to palliative orthovoltage radiotherapy
• Anticipated life expectancy ≥ 30 days and anticipated capacity for follow up for ≥ 30 days
• Negative pregnancy test done ≤ 28 days prior to registration, for biological women of childbearing potential only
• Willing to provide written informed consent
• Willing to allow baseline and follow up photograph acquisition for response and toxicity assessment
• Willing and able to return to enrolling institution for follow-up during the active monitoring phase of the study
• Willing to provide blood and tissue samples for correlative research purposes

Exclusion criteria

• Hematologic, germ cell, or any other tumor that the investigational team would deem to have a high likelihood of clinical complete response with standard palliative radiotherapy (8 Gy in 1, 30 Gy in 10, etc.)
• COHORT A (INTACT SKIN) ONLY: Prior radiotherapy targeting the lesion presenting for treatment or prior adjacent radiotherapy if > 10 Gy overlaps with a portion of the planned target
• Treatment with a B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor, monoclonal antibodies targeting vascular endothelial growth factor (VEGF) (bevacizumab or ramucirumab) or small molecule inhibitors inhibiting VEGF within the last 2 weeks or planned treatment with BRAF inhibitor within 4 weeks after radiation
• Treatment with an investigational drug therapy within 2 weeks prior to or 4 weeks (the DLT monitoring period) after MBRT
• Any tumor with direct extension into the spine such that targeting the spine/spinal cord could not be avoided

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT07062003 · GMROR2471 · 24-004810 · MBRT1

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗